Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jul 1;65(1):158-161.
doi: 10.1093/cid/cix014.

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M Munita  1   2   3 , Samuel L Aitken  1   4 , William R Miller  1   2 , Federico Perez  5 , Rossana Rosa  6   7 , Luis A Shimose  6   7 , Paola N Lichtenberger  7 , Lilian M Abbo  6   7 , Rupali Jain  8 , Masayuki Nigo  2 , Audrey Wanger  9 , Rafael Araos  3 , Truc T Tran  1   2 , Javier Adachi  10 , Robert Rakita  11 , Samuel Shelburne  10 , Robert A Bonomo  5 , Cesar A Arias  1   2   12
Affiliations
Multicenter Study

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M Munita et al. Clin Infect Dis. .

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

Keywords: P. aeruginosa; carbapenem resistant; ceftolozane; multidrug resistant.

PubMed Disclaimer

References

    1. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234–41. - PMC - PubMed
    1. ZERBAXA (ceftolozane/tazobactam) product package insert. Whitehouse Station, NJ: Merck, 2014.
    1. Sutherland CA, Nicolau DP. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther 2015; 37:1564–71. - PubMed
    1. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013; 57:5707–9. - PMC - PubMed
    1. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 2013; 57:6305–10. - PMC - PubMed

Publication types

MeSH terms